| | | 00681 | | 01.04.2004 | | GlaxoSmithKline AG | | | | | | | | | | | | | 08.08. | | | | 08.08. | | FI |
| | Seq.-Nr. | Präparat | Beschreibung | Galenische Form | ATC-Klassierung | |
|---|
| 01 | Boostrix Polio | Injektionssuspension | (Vaccinum Diphtheriae Adsorbatum 0 , Vaccinum Tetani Adsorbatum 0 , Vaccinum Pertussis Acell. Adsorbatum 0 , Vaccinum Poliomyelitidis Inactivatum (Salk typ I, II, III) 0 ) | J07CA02 | | | 02 | Boostrix Polio | | (Toxoidum Diphtheriae 2 UI, Toxoidum Tetani 20 UI, Toxoidum Pertussis 8 mcg, Vaccinum Poliomyelitidis Inactivatum (Salk typ I, II, III) 80 U) | | |
|
|
